Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE versus QNASL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE versus QNASL.
HYDROCORTISONE vs QNASL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. This results in anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive effects. It also modulates carbohydrate, protein, and lipid metabolism.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins and leukotrienes, and reducing nasal inflammation.
Oral: 10-20 mg every 6-8 hours; IV/IM: 100-500 mg every 2-6 hours for acute conditions; typical maintenance: 20-240 mg/day divided every 8-12 hours.
1 to 2 sprays (80 mcg/spray) per nostril once daily; maximum 2 sprays/nostril/day.
None Documented
None Documented
Clinical Note
moderateHydrocortisone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin."
Clinical Note
moderateHydrocortisone + Rosoxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin."
Clinical Note
moderateHydrocortisone + Levofloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life: 1.5–2 hours (plasma). In tissues, biologic half-life is 8–12 hours due to intracellular activity. Half-life prolonged in hepatic impairment.
The terminal elimination half-life is approximately 8-10 hours in healthy adults, supporting twice-daily administration for systemic effects; however, intranasal administration results in minimal systemic absorption, and local half-life in nasal tissues is not well characterized.
Renal: primarily as inactive metabolites (cortisone, tetrahydrocortisone) and unchanged drug (<1%). Biliary/fecal: minimal (<5%).
The majority of a dose (approximately 40-50%) is excreted in feces as unchanged drug and metabolites, with about 10-15% excreted in urine as metabolites. Biliary excretion is the primary route of elimination.
Category D/X
Category C
Corticosteroid
Corticosteroid
Hydrocortisone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin."